Table 1. Relationships between the expression of SFRP1, β-catenin and clinicopathologic features in human biliary tract cancer.
| Clinicopathologic features | |||||||
| n | SFRP1 | P | β-catenin | P | |||
| Negative n = 52 | Positive n = 26 | Negative | Positive | ||||
| Gender | |||||||
| Male | 34 | 20 | 14 | 0.196 | 10 | 24 | 0.661 |
| Female | 44 | 32 | 12 | 15 | 29 | ||
| Age (years) | |||||||
| <60 | 32 | 22 | 10 | 8 | 24 | 0.266 | |
| ≥60 | 46 | 30 | 16 | 0.745 | 17 | 29 | |
| TNM stage | |||||||
| I | 10 | 7 | 3 | 0.182 | 4 | 6 | 0.039 |
| II | 24 | 18 | 6 | 4 | 20 | ||
| III | 16 | 7 | 9 | 3 | 13 | ||
| IVa | 28 | 20 | 8 | 14 | 14 | ||
| Histological type | |||||||
| Adenocarcinoma | 70 | 44 | 26 | 0.01 | 24 | 46 | 0.05 |
| Mcinous adenocarcinoma | 5 | 5 | 0 | 1 | 4 | ||
| Papillary carcinoma | 3 | 3 | 0 | 0 | 3 | ||
| Anatomical distribution | |||||||
| Intrahepatic | 20 | 14 | 6 | 0.599 | 5 | 15 | 0.233 |
| Perihilar | 31 | 22 | 9 | 8 | 23 | ||
| Distal | 27 | 16 | 11 | 12 | 15 | ||
| Lymph node invasion | |||||||
| Present | 47 | 36 | 11 | 0.022 | 5 | 37 | 0.012 |
| Absent | 31 | 16 | 15 | 12 | 16 | ||
| Differentiation grade | |||||||
| Well/moderately | 36 | 20 | 16 | 0.054 | 12 | 24 | 0.822 |
| Poorly/undifferentiated | 42 | 32 | 10 | 13 | 29 | ||
| Metastasis after surgery | |||||||
| + | 44 | 28 | 16 | 0.518 | 14 | 30 | 0.960 |
| − | 34 | 24 | 10 | 11 | 23 | ||
| Survival rate | |||||||
| >3 years | 32 | 16 | 16 | 0.009 | 15 | 17 | 0.019 |
| ≤3 years | 46 | 36 | 10 | 10 | 36 | ||
| Serum CEA level | |||||||
| >5 ng/ml | 45 | 27 | 18 | 0.145 | 14 | 31 | 0.835 |
| ≤5 ng/ml | 33 | 25 | 8 | 11 | 22 | ||
| Serum CA19-9 level | |||||||
| >37 U/ml | 48 | 31 | 17 | 0.622 | 15 | 33 | 0.848 |
| ≤37 U/ml | 30 | 21 | 9 | 10 | 20 | ||
| HBV infection | |||||||
| + | 40 | 25 | 15 | 0.423 | 13 | 27 | 0.931 |
| − | 38 | 27 | 11 | 12 | 26 | ||